Today: 13 June 2026
CapitaLand Investment (SGX:9CI) stock ends week higher — what to watch before Feb 11 results
10 January 2026
1 min read

CapitaLand Investment (SGX:9CI) stock ends week higher — what to watch before Feb 11 results

Singapore, Jan 10, 2026, 14:57 SGT — Market closed

CapitaLand Investment Limited (SGX:9CI) saw its shares climb 1.8% to finish at S$2.89 on Friday, up from S$2.84 the previous session. The stock fluctuated between S$2.84 and S$2.92 during the day. Trading volume hit roughly 20.4 million shares.

With the Singapore market closed for the weekend, focus now turns to full-year results set for release on Feb 11 before the open, according to an SGX notice. Ahead of those, several CLI-managed listed funds will report, starting with CapitaLand Malaysia Trust on Jan 28, followed by CapitaLand Ascott Trust on Jan 29.

CLI announced on Thursday plans to develop a S$260 million automated logistics hub in Singapore via its CapitaLand South-east Asia Logistics Fund, targeting completion by 2028. The company also secured a minority stake in smart logistics firm Ally Logistic Property, which will operate the facility under a master lease featuring built-in rent increases, The Business Times reported.

The broader market held steady. Singapore’s Straits Times Index ticked up 0.1% on Jan 9 as regional markets gained ground. Traders kept an eye on a potential U.S. Supreme Court decision related to President Donald Trump’s tariffs. “Tariffs are not going anywhere,” said Neil Wilson, UK investment strategist at Saxo Markets. The Straits Times

Behind the scenes, the Monetary Authority of Singapore is seeking input on legal reforms designed to simplify dual listings on SGX and Nasdaq. This includes a proposed safe-harbour framework for share buybacks. The consultation is part of a wider effort to attract more issuers and boost trading activity.

Investors in CLI will focus on clear updates around fundraising, fee income, and the speed of capital recycling into key targets like logistics. After the recent rally, the stock is now testing last week’s highs, and a move above that level could attract fresh short-term buying.

The upside hinges on the cycle holding steady. Any drop in trade, stubbornly high rates, or turbulence in property funding could hit demand for new logistics space and pinch returns, even in “new economy” warehouses. Plus, long construction timelines add plenty of execution risk.

Stock Market Today

  • Altria Shares Recover Ahead of Ex-Dividend Date and July Earnings
    June 13, 2026, 4:00 PM EDT. Altria Group Inc (MO) shares rose 0.74% to $71.94 on June 12, recouping Thursday's 2.35% drop. The stock approaches its ex-dividend date on June 15, with a quarterly payout of $1.06 and a dividend yield near 5.9%. Investors weigh its valuation-12-month price target aligns with current trading-and upcoming Q2 earnings call on July 30. Altria trades more as an income stock than a growth name, with a price-to-earnings ratio around 15.0. The company reaffirmed 2026 EPS guidance and reported strong Q1 results, highlighting stable revenue and adjusted EPS growth. Altria's cash returns include dividends and a $2 billion share buyback program, supporting shareholder value amid regulatory and market risks in the tobacco sector.

Latest articles

KLA Jumps After 10-for-1 Stock Split; AI Chip Boom Lifts Hopes on Tools

KLA Jumps After 10-for-1 Stock Split; AI Chip Boom Lifts Hopes on Tools

13 June 2026
KLA soared 5.55% to $254.54 on its first split-adjusted day after a 10-for-1 stock split and analyst price target hikes tied to AI-driven chip equipment demand, but with the stock now above several split-adjusted targets, investors face heightened risk ahead of the fiscal Q4 report, which will be the next key catalyst for revenue, earnings, and AI-linked demand guidance.
Pfizer trades around $26 with dividend in focus, drug-price worries linger

Pfizer trades around $26 with dividend in focus, drug-price worries linger

13 June 2026
Pfizer closed at $26.21, up 0.15%, outperforming the Health Care Select Sector SPDR ETF despite new German drug-pricing pressures and a European legal setback; investors are focused on the 6.56% dividend yield, reaffirmed 2026 guidance, and pipeline progress in obesity and oncology as Q2 earnings on August 4 approach.
Adobe stock slides on BMO downgrade: “no clear catalyst” and competition in focus
Previous Story

Adobe stock slides on BMO downgrade: “no clear catalyst” and competition in focus

Lloyds share price clings to £1 as investors eye inflation data and Jan 29 results
Next Story

Lloyds share price clings to £1 as investors eye inflation data and Jan 29 results

Go toTop